** Shares of vaccine maker Moderna MRNA.O fall 6.1% to $26.81
** Co pushes back the time frame for likely approval of a combination vaccine meant to protect against both COVID-19 and influenza
** "It's not directly clear how MRNA will be impacted by HHS (Department of Health and Human Services) requirements for placebo studies for "new" vaccines... Flu will not need placebo per HHS. But overall, changes by HHS bring uncertainty for the landscape and investors" - brokerage Jefferies
** MRNA posts Q1 adj loss of $2.52/shr, smaller than Wall Street estimates for a loss of $3.14/shr - LSEG
** Co brings in $108 mln in Q1 revenue, slightly ahead of analysts' expectations of $106.2 mln
** Including session's move, stock down 33.9% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。